CYKLOKAPRON Tablets and Injection are indicated in patients with hemophilia for short term use (two to eight days) to reduce or prevent hemorrhage and reduce the need for replacement therapy during and following tooth extraction.

Immediately before dental extraction in patients with hemophilia, administer 10mg per kg body weight of CYKLOKAPRON intravenously together with replacement therapy (see PRECAUTIONS). Following surgery, a dose of 25mg perkg body weight may be given orally three or four times daily for 2 to 8 days.

Alternatively, tranexamic acid can be administered entirely orally, 25 mg perkg body weight 3 to 4 times a day beginning one day prior to surgery.

Parenteral therapy, 10 mg per kg body weight 3 to 4 times daily can be used for patients unable to take oral medication.

Note: For patients with moderate to severe impaired renal function, the following dosages are recommended:

For intravenous infusion, CYKLOKAPRON Injection may be mixed with most solutions for infusion such as electrolyte solutions, carbohydrate solutions, amino acid solutions and Dextran solutions. The mixture should be prepared the same day the solution is to be used. Heparin may be added to CYKLOKAPRON Injection. CYKLOKAPRON Injection should NOT be mixed with blood. The drug is a synthetic amino acid, and should NOT be mixed with solutions containing penicillin.

CYKLOKAPRON Tablets 500 mg (flat, white, round with beveled edges, arcs above and below the letters CY)

NDC 0013-0114-00 100 tablets.

CYKLOKAPRON Injection 100 mg/mL

NDC 0013-1114-10 10 x 10 mL ampules

Store at 25°C (77°F); excursions permitted to 15°-30°C (59°-86°F) [see USP Controlled Room Temperature].

Manufactured for: Pharmacia & Upjohn Company, A subsidiary of Pharmacia Corporation, Kalamazoo, MI 49001, USA, By: Pharmacia NV/SA Puurs, Belgium, Revised December 2001, 818 309 101

Bookmark this page: